| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2082864 | Drug Discovery Today: Therapeutic Strategies | 2012 | 5 Pages |
Abstract
As overactive bladder (OAB) is highly prevalent and greatly impacts quality of life (QoL), effective therapeutic options are a welcome addition to the treatment algorithm. Recent evidence suggests that newer antimuscarinic agents are not only superior to placebo in the treatment of OAB, but may also have a role in treating OAB in the elderly and improve nocturia and sleep quality. While most adverse events (AEs) exceed those of placebo, cessation of therapy is infrequent.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Biotechnology
Authors
Alex Gomelsky, Roger R. Dmochowski,